Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Optinose (OPTN)
:OPTN
Holding OPTN?
Track your performance easily
Earnings Data
Report Date
Mar 06, 2025TBA Not Confirmed
Period Ending
2024 (Q4)Consensus EPS Forecast
-0.75Last Year’s EPS
-1.35Same Quarter Last Year
Moderate Buy
Based on 2 Analysts Ratings
---
Earnings Call Summary
Earnings Call Date:Nov 13, 2018
|% Change Since: -50.09%
|Next Earnings Date:Aug 14, 2018
Earnings Call Sentiment|Neutral
The earnings call presented a mixed picture. While there are positive trends in prescription growth and revenue per prescription, the overall financial performance did not meet expectations, resulting in a downward revision of revenue guidance. There are also operational challenges in prescription fulfillment and prior authorization requirements.Company Guidance
During the OptiNose Q3 2024 earnings call, the company adjusted its full-year revenue guidance for XHANCE, projecting net revenues between $75 million and $79 million, down from previous expectations of $85 million to $90 million. This revision reflects a third-quarter net revenue of $20.4 million, a slight increase from $19.8 million in Q3 2023, and a 3% growth year-over-year. The average net revenue per prescription rose to $320, marking a 36% increase from the prior year's Q3. Despite some challenges, including inventory stocking effects and slower-than-anticipated uptake, the company observed an inflection in new prescriptions, indicating potential growth. OptiNose also highlighted improvements in insurance coverage, such as XHANCE's inclusion in Express Scripts' national formularies, enhancing patient access and reducing prior authorization burdens. The company remains optimistic about achieving peak annual net revenues of at least $300 million with further market penetration.New Inflection in Prescription Growth
XHANCE observed a 20% to 40% growth in new prescriptions during October, indicating a positive trend in demand.
Increased Average Net Revenue Per Prescription
The average net revenue per prescription increased to $320 in Q3 2024, a 36% rise compared to Q3 2023.
New Insurance Coverage with Express Scripts
XHANCE was added to Express Scripts' national formularies, improving insurance coverage for over 24 million lives.
Operating Expense Control
Operating expenses for 2024 are expected to be $90 million to $93 million, reduced from the previous guidance of $95 million to $101 million.
---
OPTN Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
---
OPTN Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
| Nov 12, 2024 | $11.52 | $9.00 | -21.87% |
| Aug 08, 2024 | $15.75 | $14.25 | -9.52% |
| May 14, 2024 | $17.55 | $16.95 | -3.42% |
| Mar 07, 2024 | $26.25 | $25.80 | -1.71% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
---
FAQ
When does Optinose (OPTN) report earnings?
Optinose (OPTN) is schdueled to report earning on Mar 06, 2025, TBA Not Confirmed.
What is Optinose (OPTN) earnings time?
Optinose (OPTN) earnings time is at Mar 06, 2025, TBA Not Confirmed.
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is OPTN EPS forecast?
OPTN EPS forecast for the fiscal quarter 2024 (Q4) is -0.75.
---